Patients w/ ischemic heart disease, risk factors for heart disease, HTN, hyperlipidemia, diabetes, smoking, peripheral arterial disease. Use the lowest effective dose for the shortest duration of treatment considering the CV risk. Discontinue treatment in case of appearance of skin rash & signs of hypersensitivity. Potential for GI & renal toxicities. Avoid use during 3rd trimester of pregnancy. May adversely affect pregnancy & may cause uterine inertia & premature closure of ductus arteriosus. Increased risk of spontaneous abortion after use of prostaglandin synthesis inhibitors in early pregnancy. Potential for adverse reactions in nursing infants; discontinue nursing or the drug taking into account the expected benefit of the drug to the mother.
Sign Out
